Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 3072-3074

  Tahara, Nobuhiro ^a   Yamagishi, Sho Ichi ^a   Tahara, Atsuko ^a   Takeuchi, Masayoshi ^b   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

ADMA; Atherosclerosis; PEDF; sRAGE

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PIGMENT EPITHELIUM DERIVED FACTOR; URIC ACID;

ADULT; ARTERIAL WALL THICKNESS; ATHEROGENESIS; BLOOD SAMPLING; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCREENING; UPREGULATION; WAIST CIRCUMFERENCE;

ADMA; ATHEROSCLEROSIS; PEDF; SRAGE;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; EYE PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NITRIC OXIDE SYNTHASE; RECEPTORS, IMMUNOLOGIC; SERPINS;

EID: 84883803802     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.070     Document Type: Article

References (13)

1. S. Yamagishi, and T. Matsui Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy - friend or foe? Pharmacol Res 64 2011 187 194
2. S. Yamagishi, S. Ueda, and K. Nakamura Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications Curr Pharm Des 14 2008 2613 2618
3. H. Miyazaki, H. Matsuoka, and J.P. Cooke Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis Circulation 99 1999 1141 1146
4. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299
5. A. Bierhaus, M.A. Hofmann, R. Ziegler, and P.P. Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovasc Res 37 1998 586 600
6. Y. Ishibashi, S. Yamagishi, and T. Matsui Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level Metabolism 61 2012 1067 1072
7. J. Tombran-Tink, C.G. Chader, and L.V. Johnson PEDF: pigment epithelium-derived factor with potent neuronal differentiative activity Exp Eye Res 53 1991 411 414
8. S. Yamagishi, T. Matsui, and K. Nakamura Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders Curr Pharm Des 15 2009 1027 1033
9. N. Tahara, S. Yamagishi, and A. Tahara Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation Int J Cardiol 158 2012 461 462
10. S. Yamagishi, and T. Matsui Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker Front Biosci (Elite Ed) 2 2010 1184 1195
11. N. Tahara, S. Yamagishi, and A. Tahara Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans Atherosclerosis 219 2011 311 315
12. T. Nakamura, E. Sato, and N. Fujiwara Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients Metabolism 58 2009 1624 1628
13. S. Yamagishi, H. Adachi, and A. Abe Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome J Clin Endocrinol Metab 91 2006 2447 2450